サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1672107

世界の臨床試験市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

Global Clinical Trials Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 248 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
世界の臨床試験市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 248 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の臨床試験市場規模は、2024年の3億2,080万米ドルから2033年には5億3,603万米ドルに成長し、2026年から2033年の予測期間中に5.87％の堅調な年間平均成長率（CAGR）を示すと予測されます。

臨床試験市場は、革新的な治療法に対する需要の高まりと、安全性と有効性を確保するための厳格な試験の必要性によって、大きな成長を遂げています。バイオ医薬品産業が拡大を続ける中、医薬品開発プロセスにおける臨床試験の重要性はいくら強調してもし過ぎることはないです。これらの臨床試験は、新しい治療を評価し、多様な集団に対する効果を理解し、規制当局の承認を得るために不可欠です。個別化医療と標的治療への注目の高まりは、研究開発が個々の患者のニーズに合わせた治療法の開発を目指す中で、臨床試験の需要をさらに押し上げています。

さらに、テクノロジーの進歩が臨床試験の状況を変えつつあります。遠隔医療、電子データ収集、モバイルヘルスアプリケーションなどのデジタルヘルスソリューションの統合は、臨床試験プロセスを合理化し、患者関与を強化しています。これらの技術革新は、データ収集と分析の効率を向上させるだけでなく、遠隔地からの参加を容易にし、臨床試験をより広範な患者にとって利用しやすいものにしています。臨床試験市場が進化を続ける中、継続的な研究開発の取り組みは、医薬品開発プロセスをサポートするために利用可能な手法や技術の幅を広げる上で重要な役割を果たすと思われます。

さらに、患者中心のアプローチが重視されるようになり、臨床試験市場が形成されつつあります。ヘルスケアプロバイダーや研究者が患者の意見や経験の重要性を認識するようになるにつれ、臨床試験のデザインや実施は参加者のニーズや嗜好により重点を置くようになっています。このような患者中心主義へのシフトには、臨床試験のデザイン段階で患者からのフィードバックを取り入れ、プロトコルが患者の期待や快適さのレベルに沿うようにすることが含まれます。患者の参加と満足を優先することで、臨床試験はリクルート率とリテンション率を高め、最終的には、より確実で信頼性の高い結果を導くことができます。市場が進化し続ける中、患者の視点を統合することは、イノベーションを推進し、臨床試験の全体的な有効性を向上させる上で重要な役割を果たすでしょう。

当社のレポートは、様々な業界や市場に関する包括的かつ実用的な洞察をクライアントに提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます：

市場概要：市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクション

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、最終用途、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場プレイヤーの包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 臨床試験産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 世界の臨床試験市場分析：フェーズ別

  • フェーズ別概要
  • フェーズ別の過去および予測データ分析
  • フェーズi
  • フェーズII
  • フェーズIII
  • フェーズIV

第6章 世界の臨床試験市場分析：適応症別

  • 適応症別概要
  • 適応症別の過去および予測データ分析
  • 自己免疫/炎症
  • 疼痛管理
  • 腫瘍学
  • 中枢神経系疾患
  • 糖尿病
  • 肥満症
  • 循環器
  • その他

第7章 世界の臨床試験市場分析：デザイン別

  • デザイン別概要
  • デザイン別の過去および予測データ分析
  • 介入試験
  • 治療研究
  • 観察研究
  • 拡大アクセス

第8章 世界の臨床試験市場分析：最終用途別

  • 最終用途別概要
  • 最終用途別の過去および予測データ分析
  • 病院
  • 研究所
  • クリニック

第9章 世界の臨床試験市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他

第10章 臨床試験企業の競合情勢

  • 臨床試験市場の競合
  • 提携/協力/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Laboratory Corporation Of America Holdings（LabCorp）
  • ICON Plc.
  • Parexel International Corporation
  • Pfizer Inc.
  • PPD Inc.
  • IQVIA
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly And Company
  • Novo Nordisk A/S
  • Clinipace
  • Alcami Corporation Inc.
  • Accell Clinical Research LLC
  • Congenix LLP
  • Labcorp Drug Development
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Phase (Units and USD MN)
  • Phase I Market Sales By Geography (Units and USD MN)
  • Phase II Market Sales By Geography (Units and USD MN)
  • Phase III Market Sales By Geography (Units and USD MN)
  • Phase IV Market Sales By Geography (Units and USD MN)
  • Analysis By Indication (Units and USD MN)
  • Autoimmune/inflammation Market Sales By Geography (Units and USD MN)
  • Pain management Market Sales By Geography (Units and USD MN)
  • Oncology Market Sales By Geography (Units and USD MN)
  • CNS condition Market Sales By Geography (Units and USD MN)
  • Diabetes Market Sales By Geography (Units and USD MN)
  • Obesity Market Sales By Geography (Units and USD MN)
  • Cardiovascular Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Analysis By Design (Units and USD MN)
  • Interventional Market Sales By Geography (Units and USD MN)
  • Treatment studies Market Sales By Geography (Units and USD MN)
  • Observational studies Market Sales By Geography (Units and USD MN)
  • Expanded access Market Sales By Geography (Units and USD MN)
  • Analysis By End-Users (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Laboratories Market Sales By Geography (Units and USD MN)
  • Clinics Market Sales By Geography (Units and USD MN)
  • Global Clinical Trials Market Sales By Geography (Units and USD MN)
  • North America Market Analysis (Units and USD MN)
  • United States Market Analysis (Units and USD MN)
  • Canada Market Analysis (Units and USD MN)
  • Mexico Market Analysis (Units and USD MN)
  • Europe Market Analysis (Units and USD MN)
  • Europe Market Estimate By Country (Units and USD MN)
  • United Kingdom Market Analysis (Units and USD MN)
  • France Market Analysis (Units and USD MN)
  • Germany Market Analysis (Units and USD MN)
  • Italy Market Analysis (Units and USD MN)
  • Russia Market Analysis (Units and USD MN)
  • Spain Market Analysis (Units and USD MN)
  • Rest of Europe Market Analysis (Units and USD MN)
  • Asia Pacific Market Analysis (Units and USD MN)
  • China Market Analysis (Units and USD MN)
  • Japan Market Analysis (Units and USD MN)
  • India Market Analysis (Units and USD MN)
  • South Korea Market Analysis (Units and USD MN)
  • Australia Market Analysis (Units and USD MN)
  • South East Asia Market Analysis (Units and USD MN)
  • Rest of Asia Pacific Market Analysis (Units and USD MN)
  • Latin America Market Analysis (Units and USD MN)
  • Brazil Market Analysis (Units and USD MN)
  • Argentina Market Analysis (Units and USD MN)
  • Peru Market Analysis (Units and USD MN)
  • Chile Market Analysis (Units and USD MN)
  • Rest of Latin America Market Analysis (Units and USD MN)
  • Middle East & Africa Market Analysis (Units and USD MN)
  • Saudi Arabia Market Analysis (Units and USD MN)
  • UAE Market Analysis (Units and USD MN)
  • Israel Market Analysis (Units and USD MN)
  • South Africa Market Analysis (Units and USD MN)
  • Rest of Middle East and Africa Market Analysis (Units and USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Clinical Trials Report
  • Market Research Process
  • Market Research Methodology
  • Global Clinical Trials Market Size, By Region (Units and USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Phase
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Design
  • Market Attractiveness Analysis By End-Users
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Phase (Units and USD MN)
  • Phase I Market Sales By Geography (Units and USD MN)
  • Phase II Market Sales By Geography (Units and USD MN)
  • Phase III Market Sales By Geography (Units and USD MN)
  • Phase IV Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Indication (Units and USD MN)
  • Autoimmune/inflammation Market Sales By Geography (Units and USD MN)
  • Pain management Market Sales By Geography (Units and USD MN)
  • Oncology Market Sales By Geography (Units and USD MN)
  • CNS condition Market Sales By Geography (Units and USD MN)
  • Diabetes Market Sales By Geography (Units and USD MN)
  • Obesity Market Sales By Geography (Units and USD MN)
  • Cardiovascular Market Sales By Geography (Units and USD MN)
  • Others Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By Design (Units and USD MN)
  • Interventional Market Sales By Geography (Units and USD MN)
  • Treatment studies Market Sales By Geography (Units and USD MN)
  • Observational studies Market Sales By Geography (Units and USD MN)
  • Expanded access Market Sales By Geography (Units and USD MN)
  • Global Market Analysis By End-Users (Units and USD MN)
  • Hospitals Market Sales By Geography (Units and USD MN)
  • Laboratories Market Sales By Geography (Units and USD MN)
  • Clinics Market Sales By Geography (Units and USD MN)
  • Global Market Sales (Units and USD MN)
  • North America Market Sales (Units and USD MN)
  • Europe Market Sales (Units and USD MN)
  • Asia Pacific Market Sales (Units and USD MN)
  • Latin America Market Sales (Units and USD MN)
  • Middle East & Africa Market Sales (Units and USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11210536

Global Clinical Trials Market size is anticipated to grow from USD 320.8 Million in 2024 to USD 536.03 Million by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.87% during the forecast period of 2026 to 2033.

The clinical trials market is experiencing significant growth, driven by the increasing demand for innovative therapies and the need for rigorous testing to ensure safety and efficacy. As the biopharmaceutical industry continues to expand, the importance of clinical trials in the drug development process cannot be overstated. These trials are essential for evaluating new treatments, understanding their effects on diverse populations, and obtaining regulatory approval. The growing focus on personalized medicine and targeted therapies is further propelling the demand for clinical trials, as researchers seek to develop treatments tailored to individual patient needs.

Moreover, advancements in technology are transforming the clinical trials landscape. The integration of digital health solutions, such as telemedicine, electronic data capture, and mobile health applications, is streamlining the trial process and enhancing patient engagement. These innovations not only improve the efficiency of data collection and analysis but also facilitate remote participation, making clinical trials more accessible to a broader range of patients. As the clinical trials market continues to evolve, ongoing research and development efforts will play a crucial role in expanding the range of methodologies and technologies available to support the drug development process.

Additionally, the growing emphasis on patient-centric approaches is shaping the clinical trials market. As healthcare providers and researchers increasingly recognize the importance of patient input and experience, the design and execution of clinical trials are becoming more focused on the needs and preferences of participants. This shift towards patient-centricity involves incorporating feedback from patients during the trial design phase, ensuring that protocols are aligned with their expectations and comfort levels. By prioritizing patient engagement and satisfaction, clinical trials can enhance recruitment and retention rates, ultimately leading to more robust and reliable results. As the market continues to evolve, the integration of patient perspectives will be instrumental in driving innovation and improving the overall effectiveness of clinical trials.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • Autoimmune/inflammation
  • Pain management
  • Oncology
  • CNS condition
  • Diabetes
  • Obesity
  • Cardiovascular
  • Others

By Design

  • Interventional
  • Treatment studies
  • Observational studies
  • Expanded access

By End-Users

  • Hospitals
  • Laboratories
  • Clinics
  • COMPANIES PROFILED
  • Laboratory Corporation of America Holdings (LabCorp)
  • ICON Plc.
  • Parexel International Corporation
  • Pfizer Inc.
  • PPD Inc.
  • IQVIA
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Clinipace
  • Alcami Corporation Inc.
  • Accell Clinical Research LLC
  • Congenix LLP
  • Labcorp Drug Development
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CLINICAL TRIALS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Phase
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Design
    • 3.7.4 Market Attractiveness Analysis By End-Users
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY PHASE

  • 5.1. Overview By Phase
  • 5.2. Historical and Forecast Data Analysis By Phase
  • 5.3. Phase I Historic and Forecast Sales By Regions
  • 5.4. Phase II Historic and Forecast Sales By Regions
  • 5.5. Phase III Historic and Forecast Sales By Regions
  • 5.6. Phase IV Historic and Forecast Sales By Regions

6. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data Analysis By Indication
  • 6.3. Autoimmune/inflammation Historic and Forecast Sales By Regions
  • 6.4. Pain management Historic and Forecast Sales By Regions
  • 6.5. Oncology Historic and Forecast Sales By Regions
  • 6.6. CNS condition Historic and Forecast Sales By Regions
  • 6.7. Diabetes Historic and Forecast Sales By Regions
  • 6.8. Obesity Historic and Forecast Sales By Regions
  • 6.9. Cardiovascular Historic and Forecast Sales By Regions
  • 6.10. Others Historic and Forecast Sales By Regions

7. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY DESIGN

  • 7.1. Overview By Design
  • 7.2. Historical and Forecast Data Analysis By Design
  • 7.3. Interventional Historic and Forecast Sales By Regions
  • 7.4. Treatment studies Historic and Forecast Sales By Regions
  • 7.5. Observational studies Historic and Forecast Sales By Regions
  • 7.6. Expanded access Historic and Forecast Sales By Regions

8. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY END-USERS

  • 8.1. Overview By End-Users
  • 8.2. Historical and Forecast Data Analysis By End-Users
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Laboratories Historic and Forecast Sales By Regions
  • 8.5. Clinics Historic and Forecast Sales By Regions

9. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE CLINICAL TRIALS COMPANIES

  • 10.1. Clinical Trials Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF CLINICAL TRIALS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Laboratory Corporation Of America Holdings (LabCorp)
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. ICON Plc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Parexel International Corporation
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. PPD Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. IQVIA
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Sanofi
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. F. Hoffmann-La Roche Ltd
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Eli Lilly And Company
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Novo Nordisk A/S
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Clinipace
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Alcami Corporation Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Accell Clinical Research LLC
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. Congenix LLP
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. Labcorp Drug Development
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies